The role of novel red yeast rice formulation to modulate lipid metabolism and reduce dyslipidemia and vascular disease in the JCR:LA- cp rat

Liver derived low-density lipoprotein and intestinal derived chylomicron remnant are contributors to dyslipidemia and cardiovascular disease (CVD). In clinical practice, the most common medication to reduce fasting LDL-cholesterol is statins. However, for many individuals prescribed statins, a substantial 'residual risk' of CVD remains. Therefore, effective nutraceutical approaches that have multiple targets to lower cholesterol secreted by both the liver and the intestine remain attractive.;t was observed that these active ingredients all independently reduced fasting plasma lipids. Further, the combination of these ingredients, with 1mg/kg red yeast rice, was the most effective at reducing both fasting and non-fasting plasma lipids. The findings provide pre-clinical support for the combined use of these ingredients as a nutraceutical alternative to classic lipid lowering pharmacotherapies.;The objective was to assess the lipid lowering efficacy of novel formulations: chitin-glucan, phytosterol, the red yeast rice, using a rodent model of dyslipidemia. I.